Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

The EC has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya to treat adults with ulcerative colitis (UC) ...

About 58% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin ...

WASHINGTON -- Induction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy for patients with moderately to severely active Crohn's disease, topping both ...

Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48. 3 ...

Guselkumab, the first IL-23 inhibitor with subcutaneous and intravenous options, was approved for moderate to severe Crohn disease, showing clinical remission and endoscopic response. Iptacopan ...

Further information This topic is currently suspended. Based on the information that is currently available, decision makers have agreed that the subject technology would be appropriate for ...

Medscape Medical News, March 31, 2025 HZ Risk With Psoriasis Biologics, Traditional Rxs Compared In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for ...